Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Rubius Therapeutics, Inc. (RUBY)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues | | | | | 100.0% | 100.0% | |
| Cost of goods sold | | | | | 0.0% | 0.0% | |
| Gross profit | | | | | 100.0% | 100.0% | |
| Research and development | | | | | 55.2% | 48.2% | |
| General and administrative | | | | | 42.5% | 50.0% | |
| Depreciation | | | | | 1.3% | 1.0% | |
| EBIT | | | | | -97.7% | -98.2% | |
| Pre-tax income | | | | | -95.0% | -99.5% | |
| Income taxes | | | | | 0.0% | 0.0% | |
| Net income | | | | | -95.0% | -101.0% | |
|